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Abstract
Background: Lysinuric protein intolerance (LPI) is a rare metabolic disease resulting from recessive-inherited
mutations in the SLC7A7 gene encoding the cationic amino-acids transporter subunit y+LAT1. The disease is
characterised by protein-rich food intolerance with secondary urea cycle disorder, but symptoms are
heterogeneous ranging from infiltrative lung disease, kidney failure to auto-immune complications. This
retrospective study of all cases treated at Necker Hospital (Paris, France) since 1977 describes LPI in both children
and adults in order to improve therapeutic management.
Results: Sixteen patients diagnosed with LPI (12 males, 4 females, from 9 families) were followed for a mean of 11.4
years (min-max: 0.4-37.0 years). Presenting signs were failure to thrive (n = 9), gastrointestinal disorders (n = 2),
cytopenia (n = 6), hyperammonemia (n = 10) with acute encephalopathy (n = 4) or developmental disability (n = 3),
and proteinuria (n = 1). During follow-up, 5 patients presented with acute hyperammonemia, and 8 presented with
developmental disability. Kidney disease was observed in all patients: tubulopathy (11/11), proteinuria (4/16) and
kidney failure (7/16), which was more common in older patients (mean age of onset 17.7 years, standard deviation
5.33 years), with heterogeneous patterns including a lupus nephritis. We noticed a case of myocardial infarction in a
34-year-old adult. Failure to thrive and signs of haemophagocytic-lymphohistiocytosis were almost constant.
Recurrent acute pancreatitis occurred in 2 patients. Ten patients developed an early lung disease. Six died at the
mean age of 4 years from pulmonary alveolar proteinosis. This pulmonary involvement was significantly associated
with death. Age-adjusted plasma lysine concentrations at diagnosis showed a trend toward increased values in
patients with a severe disease course and premature death (Wilcoxon p = 0.08; logrank, p = 0.17). Age at diagnosis
was a borderline predictor of overall survival (logrank, p = 0.16).
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Conclusions: As expected, early pulmonary involvement with alveolar proteinosis is frequent and severe, being
associated with an increased risk of death. Kidney disease frequently occurs in older patients. Cardiovascular and
pancreatic involvement has expanded the scope of complications. A borderline association between increased
levels of plasma lysine and poorer outome is suggested. Greater efforts at prevention are warranted to optimise the
long-term management in these patients.
Keywords: Lysinuric protein intolerance, Inborn error of metabolism, Hyperammonemia, Urea Cycle disorder,
Pulmonary alveolar proteinosis, Myocardial infarction, Hemophagocytic lymphohistiocytosis, Lysine, Lupus,
Amyloidosis
Background
Lysinuric protein intolerance (LPI; OMIM #222700) is a
rare inborn metabolic disease resulting from recessive-
inherited mutations involving the SLC7A7 gene [1, 2].
LPI has been described sporadically worldwide and has a
higher prevalence in Finland (1/60 000) [3, 4]. Defects
occur in the y+LAT1 sub-unit of the cationic amino-
acids transporter localized at the basolateral membrane
of the tubular kidney and small bowel cells, leading to
the classical hallmarks of the disease: leakage of cationic
amino-acids in the urine (arginine, ornithine, lysine)
with associated normal to low plasma levels. y+LAT1 is
also expressed in the lung and spleen and in circulating
monocytes and macrophages, which would explain the
wide spectrum of symptoms that has been described,
such as failure to thrive, protein intolerance, hepatosple-
nomegaly, osteoporosis, lung involvement, kidney failure,
immunological disorders with autoimmunity and
haemophagocytic-lymphohistiocytosis. Neurological im-
pairment has also been reported due to the secondary
urea cycle disorder. The therapeutic management is thus
focused on the preventive care of hyperammonemia and
nutritional deficiencies. Together, these approaches have
led to benefits in terms of life expectancy. Nevertheless,
there is a need to improve our management of the disease
and to describe and anticipate the problems faced by
young adults today. With this retrospective study, we
aimed to describe the multi-faceted presentation of LPI
and the current therapeutic strategies [3, 4].
Methods
Data
We performed a retrospective analysis of the medical re-
cords of all patients identified at Necker Hospital (Paris,
France) with a diagnosis of LPI from January 1977 to July
2015. The screening was performed using the CEMARA
database for rare diseases and the archives of the Metabolic
Biochemistry Department. LPI was suspected on high urin-
ary and low to normal plasma levels of arginine, ornithine
and lysine, other biochemical abnormalities, yet normal
cystine on amino-acid chromatography and a suggestive
clinical presentation (Fig. 1). Molecular investigation was
performed to identify mutations in the SLC7A7 gene. Gen-
omic DNAs were extracted from leukocytes. The nine cod-
ing exons and intron-exon boundaries of the SLC7A7 gene
(NM_001126106.2) were amplified by standard polymerase
chain reaction (PCR) and analysed by direct sequencing on
an ABI3100 automatic sequencer (Applied Biosystems,
France). The primers used for PCR and sequencing were
designed with the Primer 3 software (http://bioinfo.ut.ee/pri-
mer3-0.4.0/primer3/). The potential impact of the non-
described variant at the protein level was predicted in
silico using Polyphen 2 (http://genetics.bwh.harvar-
d.edu/pph2/).
Pulmonary disease was assessed according to the re-
sults of broncho-alveolar lavages (BAL), chest X-ray or
high-resolution computed tomography (HRCT) and lung
biopsy, when available. Renal disease was defined as the
presence of tubulopathy, microalbuminuria, proteinuria
or estimated glomerular filtration rate (GFR) less than
60 ml/min. GFR was estimated using the Schwartz for-
mula [5] for those under 16 years of age or the Modifica-
tion of Diet in Renal Disease MDRD equation [6] for
older individuals. Renal tubulopathy was defined as
Fig. 1 Diagnosis flowchart for LPI
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glycosuria with concomitant normal glycaemia and/or
beta-2-microglobulinuria. Cerebral impairment was de-
fined as developmental disability or hypotonia observed
for more than 6 consecutive months. Osteopenia was de-
fined radiologically and/or with a Z-score < -1 standard
deviation (SD) on bone densitometry. Haemophagocytic-
lymphohistiocytosis was defined according to the criteria
outlined by the HLH-2004 [7].
Statistical analyses
Fisher’s exact test was used to assess the association be-
tween qualitative variables. The Mann-Whitney test was
performed to compare groups when variables were con-
tinuous. The amino-acid levels between living and de-
ceased patients were compared by Wilcoxon test after age
adjustment of log-transformed plasma levels at diagnosis.
Siblings of index patients were included in the analyses
because they had similar outcome (3/9 premature deaths
in index cases vs. 2/5 deaths in siblings; see table). Missing
data were excluded in the statistical analyses.
Statistical analyses were performed in the R environ-
ment (cran.r-project.org/).
Ethics
This work was approved by our institutional Ethics
Committee after declaration to the Département de la
Recherche Clinique et du Développement, and informed
consent was obtained from the parents of underage pa-
tients or from adult patients.
Results (Tables 1 and 2)
Patients – Circumstances of diagnosis – Death
Sixteen patients with LPI (9 families, 12 males, 4 fe-
males), followed at the Necker Children’s Hospital from
1977 to 2015, were enrolled in the study. Five different
geographical origins were found: Maghreb (n = 4),
France (n = 2), Turkey (n = 1), Lebanon (n = 1), and
Guinea (n = 1). A consanguineous background was
known for 12/16 patients. Uneventful pregnancy, spon-
taneous delivery, and normal birth parameters were
noted in most cases (mean weight 3021 g (SD: 397 g),
mean height 49.4 cm (SD: 1.5 cm)). One girl was born
preterm due to premature labour (34th week of amenor-
rhea). Another underwent a caesarean due to breech
presentation.
The mean age at LPI diagnosis was 4.1 years (SD: 5.3
years). Patients were followed up for a mean of 11.4
years (SD: 10.4 years).
Symptoms at presentation were failure to thrive in 9/
16 patients (2 patients with chronic diarrhoea, 3 with
vomiting and anorexia associated with aversion to
protein-rich food) and hyperammonemia in 10/16 pa-
tients who were symptomatic, including hypotonia in 3
and coma in 2 patients, thrombopenia in 8/16 patients,
anaemia in 7/16 patients, and hepatosplenomegaly in
10/16 patients. Developmental disability had already
been noticed in 5 patients at diagnosis (mean age 7.0
years; range 1.5 – 16.1 years). Five patients were diag-
nosed within the context of familial screening with only
few symptoms that were limited to hepatosplenomegaly
and/or vomiting. One patient presented with proteinuria
up to 1 g/d.
Six patients (2 females and 4 males) died at a mean
age of 4.0 y (SD: 3.2 years). Whereas initial symptoms
were similar in patients from the same family, the evolu-
tion of symptoms and the prognosis were completely
different in terms of organ involvement and death within
the same family (Table 1).
Pulmonary involvement
During follow-up, infiltrative lung disease (ILD) was re-
ported in 10/16 patients. The pulmonary characteristics
of the patients have recently been published [8]. All 10
patients had pulmonary alveolar proteinosis (PAP) con-
firmed by BAL, biopsy or autopsy. Five patients also de-
veloped lung fibrosis independently from the severity of
PAP. One patient had associated alveolar haemorrhage
within the context of thrombopenia. BAL was negative
in two cases, although biopsies confirmed the diagnosis.
When performed, HRCT scan showed patterns of ILD
(7/7). Respiratory symptoms were never the initial pres-
entation of LPI. Pulmonary involvement was initially
limited to pathological imagery without symptoms in 4
patients (mean age at diagnosis 5.5 years). Although two
of them developed remittent dyspnoea with moderate
limitation of activity, these 4 patients are the only pa-
tients living, despite lung involvement (actual mean age
29.6 years). The remaining 6 patients presented with
earlier pulmonary disease (mean age at diagnosis 2.24
years). They all died from respiratory failure at a mean
age of 4.0 years (SD: 1.5 years) (Table 1). The age of PAP
onset did not differ significantly between the patients
who died and those who lived. The onset of an acute re-
spiratory failure was always associated with a viral or
bacterial pulmonary infection, and always led to death in
the short- or middle-term. PAP was significantly associ-
ated with death (p = 0.034).
Renal disease
Renal tubulopathy was observed in all screened patients
(11/11). During the follow-up, 7 patients developed a
chronic glomerular kidney disease.
Five of them have recently been reported including
one 13.8-year-old patient with a membrano-proliferative
glomerulonephritis [9]. In this patient, the presence of
immune complexes associated with C1q and C3 deposits
within the sub-endothelial space and the glomerular
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basal membrane, a positive Farr test and low comple-
ment CH50 and C4 levels first led to a diagnosis of lupus-
like nephritis treated with corticosteroids before an
atypical evolution with monoclonal IgG1 kappa deposits
on kidney biopsy. Finally, this patient partially recovered,
with persistent proteinuria (approximately 1 g/d.) after
treatment with corticosteroids, mycophenolate mofetil
and angiotensin-converting-enzyme (ACE) blocker.
Six other patients developed chronic kidney failure at
a mean age of 18.6 years (SD: 10.3 years). The mean
follow-up time from the onset of kidney failure was 8.4
years (SD: 9.4 years). Changes in the eGFR were hetero-
geneous and were not associated with the duration of
kidney disease. To date, GFR has remained above 60 ml/
min in one patient (20 years), between 30-59 ml/min in
3 patients (13.6, 18.1 and 37.8 years), between 15-29 ml/
min in 2 patients (34.6 and 37.8 years). Histological find-
ings were also heterogeneous with amyloid lesions in
one patient with a GFR estimated at 30 ml/min. Medullar
fibrosis associated with histiocytic and lymphoplasmocytic
inflammatory infiltrates in the interstitium were described
in a newly diagnosed girl with an eGFR of 45 ml/min who
is now receiving immunosuppressive therapy. At the age
of 20 years, 50% of the patients in the cohort had GFR <
90 ml/min (Fig. 2). Microalbuminuria followed by signifi-
cant glomerular proteinuria was observed in 5 patients,
reaching up to 3 g/d. in 3 patients with lupus-like neph-
ritis, amyloid deposits and unknown histology.
Haematological disorders and autoimmunity
Five patients met sufficient criteria for a diagnosis of
hemophagocytic-lymphohistiocytosis (HLH). Bone marrow
Table 2 Amino-acids values at diagnosis
Age
(years)
Patient values at diagnosis Normal range adapted with age
Plasma (μmol/l) Urine (μmol/mmol creatinine) Plasma (μmol/l) Urine (μmol/mmol creatinine)
Lys Arg Orn Lys Arg Orn Lys Arg Orn Lys Arg Orn
1 * 1.5 116 82 47 3664 305 230 89-241 34-106 24-92 16-69 <8 <8
2 * 0.8 78 82 47 NA NA NA 96-262 41-117 22-114 13-79 <11 <8
3 ** 16.2 34 14 9 32 7 2 120-268 40-124 25-125 7-58 <5 <5
5 *** 2.2 52 13 15 822 36 16 85-241 38-110 23-91 10-46 <9 <7
6 1.3 35 9 5 1372 107 31 89-241 34-106 24-92 16-69 <8 <8
8 **** 0.7 113 20 16 2990 195 67 96-262 41-117 22-114 13-79 <11 <8
9 2.2 74 17 8 1849 188 125 85-241 38-110 23-91 10-46 <9 <7
10 1.3 121 28 16 1721 231 135 89-241 34-106 24-92 16-69 <8 <8
11 12.6 33 7 10 33 7 10 141-224 35-115 20-132 10-56 <6 <6
12 3.4 77 27 11 886 155 38 85-241 38-110 23-91 10-46 <9 <7
13 **** 10.3 38 16 21 747 398 95 141-224 35-115 20-132 10-56 <6 <6
14 * 0.1 206 23 11 1504 121 58 106-246 35-91 22-154 22-171 <14 <19
15 * 0.005 177 33 69 673 129 75 106-246 35-91 22-154 22-171 <14 <19
16 *** 0.008 137 19 13 927 68 32 106-246 35-91 22-154 22-171 <14 <19
*,**,*** and **** refer to 4 different families. Cases without asterisk are from different families
Fig. 2 Death, renal disease and alveolar proteinosis observed during LPI. (percentage patient with event)
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aspirates were obtained in only 6 patients. Nevertheless,
anaemia (Hb < 10 g/dl) and thrombopenia (<100 G/l) were
reported in 7 and 5 patients, respectively. Hepatospleno-
megaly was observed in all patients. Ferritinemia and
triglyceridemia fluctuated, but pathologic concentrations
were found in 11/12 (>500 μg/l) and 10/12 patients (>3.0
mmol/L), respectively. Three patients presented with
hypofibrinogenaemia <1.5 g/L. Other signs were observed,
including transaminase abnormalities, hypoHDL-
cholesterol, and elevated lactate dehydrogenase (LDH). A
specific treatment for HLH was required for 2 patients.
Both received corticosteroids and cyclosporine, which was
efficacious in only one. Two other patients required plate-
let transfusions.
Autoimmunity, specifically lupus nephritis, vitiligo and
immune thrombocytopenic purpura, was reported in
3/16 patients.
Digestive and nutritional concerns
An aversion to protein-rich food was noticed in 9/13 pa-
tients with associated diarrhoea and vomiting leading to
episodic use of enteral nutrition for 4 patients and par-
enteral nutrition for 3. All patients (16/16) presented
with failure to thrive at a mean age of 2.0 years (SD: 3.6
years) at diagnosis. Growth-hormone improved the
height of 2/2 patients who presented with a concomitant
deficiency. Among the 11 patients with available data,
the available mean last height reached -2.51 SD (SD:
2.31). Osteopenia was reported in 12/15 patients of
whom 3 developed fractures. Finally, multiple other defi-
ciencies were also observed, such as hypocarnitinaemia
(in 3 of the 4 screened) and low plasma levels of selen-
ium (in 4 of the 5 screened).
Two patients experienced recurrent acute pancreatitis.
Triglyceridemia varied up to10.3 mmol/L, but remained
moderate in one patient during a crisis (5 mmol/L). In
this patient, an abdominal CT scan, MRI and endoscopic
ultrasound of the biliary tract and pancreas excluded
gallstones and did not find any evidence of autoimmune
reaction. No other cause was found. There was no his-
tory of alcohol consumption, the calcium and immuno-
globulin G type 4 levels were normal, and there was no
mutation in the cystic fibrosis transmembrane conduct-
ance regulator (CFTR), serine protease inhibitor kazal 1
(SPINK1) or cationic trypsinogen (PRSS1). Statin admin-
istration in one patient and taking the maximal dose of
fenofibrate or gemfibrozil in the other patient did not
prevent further episodes of pancreatitis.
Cerebral impairment
Five among 16 patients presented with acute hyperammo-
nemic encephalopathy with seizures in 4 and coma in 3
patients. Persistent hypotonia or developmental disability
was recorded for 8/14 patients without a significant
association with elevated glutamine. Another patient pre-
sented with seizures due to complicated cholesteatoma.
Cardiovascular involvement
Two severe cardiac events occurred, in two distinct pa-
tients: i) an acute inferior and inferolateral myocardial
infarction associated with diffuse coronaropathy treated
with angioplasty and active stents in the intraventricular
coronary artery, in a 34-year-old non-smoking man who
concomitantly presented with mild kidney failure and
hypertension and benefited from treatment with an ACE
inhibitor; ii) a sinus arrest revealed by fatigue and mal-
aise in a 22-year-old patient, that required a pace-maker.
The patient had no personal or familial history of car-
diac disease, hyperkalaemia or toxic ingestion. Cardiac
amyloidosis has not specifically been looked for.
Biochemical results (Table 2)
Data at diagnosis were available for 14 patients. Biochem-
ical results at diagnosis were unavailable for 2 patients
whose diagnosis was not made in our centre. The mean
plasma concentrations of lysine, arginine, ornithine and
glutamine were 90 μmol/L (SD: 53, range: 33-206), 28
μmol/L (SD: 23, range 7-82), 22 μmol/L (SD: 18, range 5-
69) and 978 μmol/L (SD: 317, range: 518-1507), respect-
ively. These results are consistent with the literature [10].
In urine, the mean concentrations of lysine, arginine and
ornithine were 1324 μmol/mmol creatinine (SD: 1057,
range: 32-3663), 150 μmol/mmol creatinine (SD: 115,
range: 7-398) and 70 μmol/mmol creatinine (SD: 64,
range: 2-230), respectively. Of note, urinary levels of di-
basic amino-acids were close to normal at presentation in
some cases (age 16.2 and 12.6y.), and increased levels were
found only on repeating the analyses because of high clin-
ical suspicion. There was a trend towards higher plasma
and urinary levels of cationic amino-acids at diagnosis in
patients who subsequently died compared to living pa-
tients (Wilcoxon, p = 0.08; logrank, p = 0.17, Fig. 3). In
addition, earlier age at diagnosis was a borderline pre-
dictor of shorter overall survival (logrank, p = 0.16; Fig. 3).
Bivariate prediction of survival by age-adjusted plasma
lysine levels and age at diagnosis suggests that their
influence on prognosis is independent and additive
(logrank, p = 0.10). Patients with PAP had a non-
significant trend towards higher plasma lysine levels
than those without PAP (Mann-Whitney, p = 0.11)
Therapeutic management
All the patients received a hypoproteinemic diet adapted
for their age from diagnosis to the last record. All were
supplemented with citrulline (mean: 106.2 mg/kg/d.; SD:
46.2) and received vitamin supplementation. Three pa-
tients transiently received lysine supplementation, 4 ar-
ginine and 4 carnitine, with no difference in prognosis.
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Seven patients received ammonia scavengers, including
sodium phenylbutyrate (n = 6) and/or sodium benzoate
(n = 3) for hyperammonemia >80 μmol/L, without a dif-
ference in terms of prognosis. All patients with PAP
underwent whole-BAL. Seven patients received cortico-
steroids, 3 within the context of respiratory failure and
HLH with no improvement in respiratory function, 2
with isolated HLH, and 2 with kidney failure with an in-
flammatory pattern on biopsy. Three adult patients re-
ceived ACE-inhibitors to control proteinuria.
Molecular investigation
We characterised genotypes of 9 LPI patients from 6
non-related families (Table 3). Five different mutations
in the SLC7A7 gene were identified, including 3 point
missense mutations (c.726G > A, c.753G > C and
c.1417C > T) and two small deletions (c.254_255delTT
and c.1185_1188delTTCT), which led to a frameshift
and created a premature stop codon. Among these 5
mutations, two were recurrent in 2 families (c.726G > A
and c.1185_1188delTTCT) [11, 12]. Only the c.753G > C
was novel. The pathogenicity of this mutation was dis-
puted based on predictive data and the existence of a
previously reported mutation in the same codon
(c.753G > T, p.Glu251Asp) [11]. Except for one patient
who carried two mutations in a heterozygous state, the
remaining patients with a known consanguineous link
(5/6 families) carried one mutation in a homozygous
state. Seven patients in the cohort did not have a mo-
lecular analysis due to the absence of a sample, but 4 in
Fig. 3 Kaplan-Meier overall survival plots for LPI patients. (red vs blue lines: patients with values above vs below a cutoff, resp., horizontal axis
unit : year). Panels a-c: patients grouped by plasma dibasic amino-acid levels above or below the patients’ median at diagnosis. Panel
d: patients grouped by age at diagnosis greater or lesser than 1.5 years. Increased age-adjusted plasma lysine and earlier age at diagnosis
were borderline predictors of poorer outcome (see text)
Table 3 Mutations in SLC7A7 gene
Family 1 2 3 4 5 6
Tested patient(s) 2, 14, 15 3, 4 16 8 10 12
Non tested related patients 1 5, 7 13
consanguinity + + + + +
Mutation(s) c.726G > A(p.Trp242*) c.753G > C (p.Glu251Asp) c.1185_1188deITTCT c.726G >
A(p.Trp242*)
c.254_255deITT c.1417C > T
(p.Arg473*)
c.1185 1188deITTCTa
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the same family were related to a least one genotyped
proband. No obvious genotype-phenotype relationship
was identified because the 6 patients who carried the
same genotype did not have the same prognosis and
organ involvement.
Discussion
Four systems have been described for cationic amino-
acids transport through plasma membrane in mammals:
y+, b0,+, B0,+ and y+L. These systems differ in terms of
specificity for amino-acids, tissue localisation and de-
pendency on sodium [10]. The y+LAT-1 and 4F2hc sub-
units heterodimerise to form the part of the y+L system
that is responsible for the exchange of cationic amino-
acids for neutral amino-acids plus sodium at the basolat-
eral plasma membrane of polarised cells, such as epithe-
lial cells of the proximal renal tubules, small bowel, lung
and leukocytes. Only mutations in the SLC7A7 gene en-
coding the y+LAT-1 subunit have been identified in LPI
patients, but no mutation has been reported in SLC3A2
encoding 4F2hc. Interestingly, cystinuria (OMIM 220100)
is also caused by defects in cationic amino-acids transport
in the b0,+system [13–15].
Initially described by Perheetupa and Visakorpi in
1965, LPI has been reported worldwide [15]. There is a
higher prevalence in Finland reaching 1/60 000. How-
ever, LPI has also been documented in Japan, Turkey,
Italy and Maghreb [3, 4, 12, 16]. As expected with an
autosomal recessive disease, inbreeding was important
in our cohort.
Since the first description of LPI, a great deal of clin-
ical heterogeneity has been observed among patients.
LPI is often revealed by the appearance of chronic di-
gestive symptoms and failure to thrive after presumptive
diagnoses of coeliac disease, other causes of malabsorp-
tion or “food allergies” [3, 4]. However, the onset can
also be sudden with hyperammonemic encephalopathy.
All but one patient had hepatosplenomegaly at diagno-
sis, a feature that should alert practitioners to the possi-
bility of LPI.
As observed in our cohort, patients from the same
family can have entirely different evolution of symptoms,
which may hinder the ability to provide a definitive
prognosis (Table 1). Inter-familial clinical heterogeneity
(alveolar proteinosis, cerebral impairment, cardiac event)
in patients displaying the same genotype (families 1 and
4, c.726G > A homozygous) is also common. To date, 51
mutations in SLC7A7 have been reported [13–15]. Here,
we report 5 different mutations, 4 of which were previ-
ously described and 1 was a novel mutation. With the
lack of a clear genotype-phenotype relationship, the
identification of mutations in patients may permit con-
firmation of the diagnosis but is not useful in predicting
the severity of the clinical course [16]. In a Finnish
transcriptomic study on 13 patients, the expression of
926 genes differed significantly from controls, involving
basic cellular functions such as cell cycle, signalling, ion
transport or apoptosis. The extent of transcriptional ef-
fects has been hypothesised to explain the variety of
symptoms observed in LPI [13]. Although 12/16 of our
patients were males, this overrepresentation was not sta-
tistically significant (Fisher’s exact test) and has not been
described in other cohorts [17, 18].
Pulmonary involvement appears to play a major role
in the prognosis of the disease. The characteristics of the
respiratory disease in our cohort were recently published
[8] and consist clinically, radiologically and histologically
of an early and persistent PAP, which, in some cases, can
be associated with fibrosis. The respiratory complica-
tions have no obvious association with the clinical or
radiologic severity of the PAP. Radiological findings usu-
ally show an interstitial or alveolo-interstitial pattern
with intralobular lines, interlobular septa thickening and
frequent cysts and ground glass opacities. Fibrosis may
develop independently from PAP. The early onset of pul-
monary disease is associated with a severe prognosis as
previously described [18]. There were more asymptom-
atic patients in the Finnish study (65%), in which chest
X-ray was used to diagnose the disease [18]. Santamaria
et al. observed that 8/9 patients were asymptomatic des-
pite the presence of infiltrative lung disease on the
HRCT-scan [17]. To date, the HRCT-scan is recom-
mended to detect lung involvement [8].
PAP is a result of defects in the surfactant homeostasis
composed of proteins and phospholipids that are synthe-
sised by type 2 pulmonary epithelial cells (PECs). PECs
are also responsible for the recycling of 70 to 80% of the
surfactant, whereas the rest is phagocyted by alveolar
macrophages (therafter, AM) or caught in the lymphatic
circulation. PAP can be either acquired or inherited. In
children, genetic causes of PAP include LPI, methionyl-
tRNA synthetase (MARS), and mutations in Granulo-
cyte-macrophage colony stimulating factor (GM-CSF) re-
ceptors genes CSF2RA and CSF2RB [19]. In adults, the
most frequent form of PAP is autoimmune and mediated
by anti-GM-CSF antibodies. In this latter form, GM-CSF
injections have been shown to be effective [20]. GM-CSF
is essential for the differentiation of AMs by enhancing
their ability to uptake and catabolise remaining surfac-
tant components. Although SLC7A7 gene expression is
enhanced by GM-CSF, AM differentiation is not im-
paired in LPI patients [21], and GM-CSF appears to be
inefficient or even dangerous in hemophagocytic-
lymphohistiocytosis (HLH) related to LPI.
In alveolar macrophages (AMs), y + LAT-1/4F2hc is
responsible for the influx of arginine [22]. y + LAT-1/
4F2hc defects lead to a decrease of intracellular arginine,
which is the main substrate for nitric oxide synthase
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(NOS), the enzyme responsible for the production of ni-
tric oxide (NO) [23]. NO plays a critical role in the lytic
processes of macrophages as well as in vasoregulation,
platelet aggregation and neurotransmission [24]. The ac-
tual paradigm for PAP-LPI is that AMs present a defect
in phagocytic function that impairs the homeostasis of
surfactant [25]. Moreover, LPI-related PAP is clearly ag-
gravated by infections. All of the children who died did
so from bacterial or viral pneumonias that complicated
PAP. It has been recently described that the Toll Like
Receptor 9 (TLR 9) pathway, which is essential for bac-
terial and viral defence, is impaired in macrophages of
patients with LPI, with decreased interferon type I pro-
duction [23]. Intracellular NO accumulation secondary
to defects in arginine transport has been proposed to ex-
plain the pro-inflammatory pattern in LPI, but Kurko re-
cently showed that the NO levels were on the contrary
decreased in patients with LPI [3, 4, 23]. In addition, the
pro-inflammatory pattern could result from the upregu-
lation of TLR2/1 and TLR4 pathways leading to higher
levels of tumor necrosis factor alpha (TNF alpha) and
interleukin-12 [23]. The role of corticosteroids also re-
mains controversial. There is no pathophysiological ra-
tional or clear benefit that justifies promoting this
treatment, which is associated with an increased risk of
infections. A prompt antibiotic regimen should therefore
be initiated after microbiological documentation of an
infection. Vaccination and physiotherapy for airway
clearance are also important in the management of this
chronic respiratory complication.
Interestingly, we were surprised to find some evidence
for a higher plasma concentration of lysine in patients
with a poor prognosis. The role of lysine or cationic
amino-acids in PAP has not clearly been determined. Be-
cause the intra-alveolar cationic amino-acid levels and
the possible role of pulmonary epithelial cells are un-
known, further elucidation of their roles has been ham-
pered. Of note, a 13-year-old boy died 26 months after a
heart-lung transplantation for LPI-AP and recurrent
PAP on the graft, which suggests that macrophages play
a major role in the pathophysiology of the disease [26].
It was recently reported that the defect of SLC7A7/y
+LAT-1 leads to the increased activity of another cat-
ionic amino-acid transporter such as SLC7A1/CAT1, as
suggested by Tringham and al., who used a transcrip-
tomic approach [13]. Nevertheless, this transporter is
expressed in the basolateral plasma membrane of epithe-
lial cells, but apparently not in AMs [22, 23, 27]. We
speculate that the lack of SLC7A1 in AMs may increase
susceptibility to lysine depletion in this cell type thereby
possibly leading to both higher risk of alveolar proteino-
sis and moderate increase of lysine levels in plasma of
patients with poorer outcome. Nevertheless, other fac-
tors would be involved to explain why plasma arginine
and ornithine are not similarly involved. Alternatively,
the association between moderate increases in lysine
levels and poorer outcome might reflect putative down-
stream regulatory mechanisms, for instance a need to
more strongly repress lysine oxydation in order to main-
tain protein synthesis. Such a putative mechanism would
lead to increased lysine during catabolic stresses.
Except for the presence of early and persistent tubular
involvement, renal disease primarily affects older patients
(mean age of onset 17.7 years; SD 9.73 years). When kid-
ney dysfunction is suspected, GFR should be actually mea-
sured rather than just estimated [28]. Glomerular
involvement with kidney failure was reported in half of
our patients after the age of 20. Despite a common geno-
type, the 3 available renal biopsies showed different histo-
logical patterns, such as glomerular amyloidosis,
interstitial fibrosis or mesangial sclerosis, consistent with a
previous report by Tanner, who evaluated a Finnish cohort
[28]. The mechanisms remain obscure. Like in our patient
with lupus nephritis, some autoimmune nephropathies as-
sociated to LPI have benefited from classical immunosup-
pressive therapy [9, 29]. Proximal tubulopathy seems to be
an early hallmark of the disease as it was observed in all of
our patients. Fanconi syndrome has also been reported,
though the underlying mechanism remains hypothetical
[30]. An elevation of intracellular lysine concentrations in
the tubule would increase tubular permeability and
enhance apoptosis through NADPH oxidase [31].
Therapeutic concerns focus on the early introduction
of ACE-blockers to diminish proteinuria and possible
hypertension [28]. Interestingly, 3 patients have success-
fully benefited from renal transplantation, as reported in
the literature [28].
Various inflammatory and auto-immune manifestations
including vasculitis can complicate LPI [32]. Interestingly,
defects of phagocytosis have been observed in circulating
LPI-associated monocytes and non-alveolar macrophages,
as described in auto-immune diseases [25, 33]. Moreover,
classical immunosuppressive treatment improves LPI
inflammatory complications [32]. Whereas the T-cell re-
sponse is normal, the humoral immune response is defect-
ive in some patients with LPI and an increased risk of
infection [34]. However, we observed only one case of
severe sepsis in our cohort.
HLH is another frequent immune complication ob-
served in LPI [3, 4]. Primary or secondary HLH is due to
an uncontrolled and self-sustained hyper-inflammatory
response involving NK-cells and cytotoxic T-lymphocytes
that leads to the uncontrolled activation of macrophages
and pro-inflammatory cytokine secretion [35]. Such cyto-
kine secretion has been reported in 4 patients with LPI
with notably high levels of soluble CD25 [36]. In our co-
hort, haemophagocytosis was histologically documented
in only 6 patients through bone marrow aspiration. Most
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of the time, HLH symptoms were limited to characteristic
splenomegaly, hypertriglyceridemia, elevations in ferritin
levels and low fibrinogen, none of which lead to further
investigation because they were not life-threatening.
Nevertheless, hypertriglyceridemia was associated with re-
current acute pancreatitis in 2 patients who did not re-
spond to treatment with statins, fibrates or gemfibrozil.
Hypertriglyceridemia is considered a risk for pancreatitis
when the levels are >1000 mg/dL (11.2 mmol/L) [37], but
the question arises of whether moderate levels can induce
pancreatitis in such patients. Interestingly, an association
between bone marrow abnormalities suggesting HLH and
pancreatitis in LPI patients has already been described
[38], underlining this hypothesis. Nevertheless the exist-
ence of predisposing factors for hypertriglyceridemia such
as Asn9 variant of lipoprotein lipase discovered in a
brotherhood among patients should remind the probable
role for other genes in the pathogenicity of the different
symptoms observed in the disease.
Failure to thrive is a hallmark of LPI and is associated
with protein depletion intrinsically associated to LPI but
also secondary to malabsorption. Growth hormone sup-
plementation was effective in patients with associated
growth hormone insufficiency as already reported [39].
Its use has not been evaluated yet in LPI. We did not
find any obvious benefit from oral supplementation with
citrulline, lysine or arginine. Although criteria for osteo-
penia were limited to bone radiography, osteopenia was
reported in the majority of the patients. Parto et al. also
described histologic signs of osteoporosis in 8/9 patients.
Collagen synthesis in skin fibroblasts was decreased. The
mechanism involved in the development of osteopenia
seems to be more associated with synthesis defects sec-
ondary to protein depletion than increase of degradation
by osteoclasts or inflammation [40]. Finally, multiple nu-
tritional deficiencies are observed in patients with LPI in
the area of global nutritional depletion. Selenium defi-
ciency can lead to myocardiopathy and myopathy [41].
Targeted nutritional monitoring is therefore essential.
A secondary urea cycle disorder with hyperammone-
mia has been well described in LPI. Indeed, low arginine
and ornithine is thought to primarily lead to the func-
tional depletion of the urea cycle intermediates [10].
More than half of the patients presented with cognitive
disorders. Though this complication has not been re-
ported in the literature, it can be easily explained by
chronic hyperammonemia. With regard to chronic dysli-
pidaemia, we did not observe any cerebral strokes,
though an unexpected myocardium infarction did occur.
This latter was definitively associated with diffuse coro-
naropathy. We are the first to report a cardiac involve-
ment but another vascular disease, moyamoya
vasculopathy, was recently described in LPI [42]. The
cycle of low plasma levels of arginine resulting in NO
depletion, decreased arterial and coronary vasodilatation
and ultimately ischemia has already been described [43].
Cardiovascular monitoring is thus necessary in young
adults with LPI who present hypertriglyceridemia, recur-
rent kidney failure and other risk factors for arterial dis-
ease. Moreover, we also report a conduction disorder
whose mechanism is obscure. Based on renal and hepatic
biopsies from 2 different patients, we noted that amyloid-
osis can complicate LPI. Whether amyloid lesions were re-
sponsible for the conduction block is unclear because
echocardiography was not as suggestive. Nonetheless, this
potential correlation urges caution.
General therapeutic management remains empirical
with 3 major axes: prevention of hyperammonemia, nu-
tritional supplementation and prevention of specific
complications. There is a general consensus that a
hypoproteinemic regimen should be initiated with an
objective of 1 g/kg/d. associated with L-citrulline sup-
plementation, L-carnitine 20-50 mg/kg/d., vitamins
and other nutritional supplementation, if necessary [3, 4].
Ammonia scavengers such as sodium benzoate or phenyl-
butyrate are used based on glutamine levels. L-citrulline is
used to correct the intracellular defect of arginine through
arginosuccinate-synthase and argininosuccinate-lyase. Be-
cause arginine was initially thought to be increased in
macrophages, the dosage of L-citrulline dosage was a sub-
ject of controversy because of the possibility that it could
increase inflammatory damages through its conversion to
arginine and NO. L-Citrulline supplementation is thus
usually limited to 100 mg/kg/d [3, 4]. Nevertheless, it was
shown that arginine and NO were actually lacking in mac-
rophages and that low plasma levels of arginine may be as-
sociated with cardiovascular disease. Therefore, the dose
may need to be reassessed. Also, an alimentation re-
stricted into long chain fatty acids and supplemented with
medium chain fatty acids is questionable, in order to de-
crease the levels of triglycerides and prevent the risk of
pancreatitis. Our data show a borderline significant associ-
ation between relatively increased lysine levels (within
normal to low values) and poor prognosis, calling for new
investigations on the mechanisms of lysine transport and
metabolism in LPI patients. Finally, this study reveals the
importance of careful renal and cardiovascular monitor-
ing. ACE-blockers and hypolipidemic agents may play an
essential role in the therapeutic management and preven-
tion of several complications.
Conclusions
This study presents a general review of LPI symptoms
and raises new questions on prognostic factors and the
evolution of the disease in young adults. PAP is an early
complication that affects the general prognosis, whereas
kidney failure develops primarily in older patients. Young
adults would benefit from systematic cardiovascular
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monitoring and general recommendations with regard to
management of dyslipidaemia and nutritional supplemen-
tations. Moreover, autoimmune complications should
systematically be discussed in the presence of atypical
symptoms as they appear accessible to classical therapeu-
tics. High plasma lysine levels show some association with
poor prognosis yet the mechanism of pathology is unclear
warranting additional investigations in different patient
cohorts and by in vitro assays.
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